Austria-based diabetes app company mySugr has raised $4.8 million from Roche Ventures and iSeed Ventures. Existing investor XLHealth also contributed to the round, which will help mySugr scale up its user base in the US and other other countries. iSeed Ventures is a new fund that has only made a half dozen investments so far, and it is led by former iHealth Lab head Adam Lin.
MySugr offers a handful of apps, but its flagship is called Diabetes Logbook, which is designed for people with type 1 or type 2 diabetes and includes logging, graphing, analysis, “exciting challenges”, “smile-inducing feedback”, and Apple Health integration. If users sign up for a month-to-month or annual subscription, pro features include additional challenges, automatic blood glucose logging from connected devices, reminders, and more report formats. Its Logbook app is registered as a class 1 device with the FDA and has similar status in Europe.